Goals of the symposium Inform the nephrology community on the state of the art of the new personalized/precision medicine treatment algorithms in slowing progression of kidney disease and the implications for randomized controlled trial design.
The symposium has been granted 11 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).
Wednesday 13 December 2017 Delegates arriving in Groningen 18.00 – 19.00 Reception and registration at DOT This reception is offered to you by the University of Groningen, the Municipality of Groningen and the Province of Groningen 19.00 – 19.10 Precision Medicine in Groningen Marian Joëls 19.10 – 19.30 Precision Medicine: how to hit the target Rick Grobbee 19:30 – 21:30 Dinner
Thursday 14 December 2017 7.30 – 8.15 Reception and registration at the UMCG 8.15 – 8.30 Welcome and goal of the conferenceHiddo Heerspink
Precision Medicine to halt renal/CV risk in diabetes The use of biomarkers The use of classical biomarkers Chairs Paul de Jong/Jos Kosterink 8.30 – 9.00 Blood pressure: a valid surrogate for renal outcome? Hans Mann 9.00 – 9.30 Glucose: a target to optimize antidiabetic therapy Mark Cooper 9.30 – 10.00 Albuminuria: a renal risk marker and target for treatment Beppe Remuzzi 10.00 – 10.30 Plenary discussion 10.30 – 11.00 Coffee Break
The use of novel biomarkers Chairs Stephan Bakker/Maria Gomez 11.00 – 11.30 New biomarkers for risk and response prediction Peter Rossing 11.30 – 12.00 A system biology approach to apply precision medicine Matthias Kretzler 12.00 – 12.30 Multiple biomarker score for precision medicine Hiddo Heerspink 12.30 – 13.00 Plenary Discussion 13:00 – 14:00 Lunch
Precision Medicine to halt renal/CV risk in diabetes Impact on clinical trial design Chairs Dennis Andress/Shahnaz Shahinfar 14.00 – 14.30 Drug development - precision based models Matt Breyer 14.30 – 15.00 Challenges with classical trial design Jim List 15.00 – 15.30 New clinical trial designs for precision medicine in CKD Vlado Perkovic 15.30 – 16.00 Plenary Discussion 16.00 – 16:30 Coffee Break
Precision Medicine to halt renal/CV risk in diabetes Regulatory implications Chairs Bert Leufkens/Peter Mol 16.30 – 17.00 Registering and approving Precision medicines in CKD Aliza Thompson 17.00 – 17.30 Precision medicine and regulatory decisions: methodological aspects Bert Leufkens 17.30 – 18.00 Implications of precision medicine for health technology assessments Maarten Postma 18:00 – 18:30 Plenary discussion 19.00 Free evening
Friday 15 December 2017
Precision Medicine to halt renal/CV risk in diabetes Impact for patients and payers Chairs Petra Denig/Meg Jardine 8.00 – 8.30 Patient goals from precision medicine Fiona Loud 8.30 – 9.00 How to pay for precision medicine Amanda Adler 9.00 – 9.30 Plenary discussion 9.30 – 10.00 Coffee Break
Precision Medicine to halt renal/CV risk in diabetes Implications for clinicians Chairs Ricardo Correa Rotter/Ron Gansevoort 10.00 – 10.30 Need to implement precision medicine in CKD Gert Mayer 10.30 – 11.00 Need to implement precision medicine in general practice Jeroen de Vries 11:00 – 11.30 Precision Medicine, the global perspective Adeera Levin 11.30 – 12.00 Plenary Discussion